Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Andrew Blauvelt, Tsen Fang Tsai, Richard G. Langley, Megan Miller, Yaung Kaung Shen, Yin You, Ya Wen Yang, Kim A. Papp, Luis Puig
Dive into the research topics of 'Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis'. Together they form a unique fingerprint.